RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway
Zhidong Huang, Kaixin Lou, Mengyang Qi, Jinhui Wang, Linwei Li, Bo Sun, Chen Wang, Xirui Zhou, Debo Chen, Hong Liu · 2024
Read RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway by Zhidong Huang, Kaixin Lou, Mengyang Qi, Jinhui Wang, Linwei Li, Bo Sun, Chen Wang, Xirui Zhou, Debo Chen, Hong Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11583401.txt.
Description
Zhidong Huang and nine co-authors hunt for a marker that shows who gains from a breast cancer drug in a 2024 paper. The drug is ribociclib, which blocks cell-cycle proteins CDK4 and CDK6. No good marker now shows which patients will gain from it. The team used machine learning on gene data to search.
Their model picked out eleven long non-coding RNAs tied to drug response. One of them, RERE-AS1, stood out in cell tests. Raising RERE-AS1 made ribociclib work harder against cancer cells. It also curbed bad traits of the cells through a growth path. Tumors with more RERE-AS1 were smaller and at a lower stage. The authors offer the RNA as a new marker for care.
Catalog record
| CREATOR | Zhidong Huang, Kaixin Lou, Mengyang Qi, Jinhui Wang, Linwei Li, Bo Sun, Chen Wang, Xirui Zhou, Debo Chen, Hong Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |